BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 49 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2023. The put-call ratio across all filers is 1.31 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $8 | -61.9% | 39 | +290.0% | 0.00% | – |
Q2 2023 | $21 | -99.8% | 10 | -99.7% | 0.00% | – |
Q1 2023 | $10,000 | -98.1% | 2,983 | -98.4% | 0.00% | – |
Q2 2022 | $516,000 | -37.6% | 187,070 | -24.0% | 0.00% | – |
Q1 2022 | $827,000 | +7.0% | 246,202 | +27.5% | 0.00% | – |
Q4 2021 | $773,000 | -47.5% | 193,166 | -56.7% | 0.00% | – |
Q3 2021 | $1,471,000 | -44.6% | 445,698 | -36.2% | 0.00% | – |
Q2 2021 | $2,653,000 | -14.0% | 698,294 | -13.3% | 0.00% | – |
Q1 2021 | $3,085,000 | +73.7% | 805,438 | +105.3% | 0.00% | – |
Q4 2020 | $1,776,000 | +932.6% | 392,417 | +3585.7% | 0.00% | – |
Q3 2020 | $172,000 | +70.3% | 10,647 | +18.7% | 0.00% | – |
Q2 2020 | $101,000 | -70.2% | 8,970 | -87.7% | 0.00% | – |
Q1 2020 | $339,000 | +3666.7% | 72,977 | +3523.5% | 0.00% | – |
Q4 2019 | $9,000 | -97.7% | 2,014 | -98.1% | 0.00% | – |
Q3 2018 | $395,000 | -22.1% | 103,506 | -20.4% | 0.00% | – |
Q2 2018 | $507,000 | +645.6% | 130,086 | +683.9% | 0.00% | – |
Q3 2017 | $68,000 | – | 16,594 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Weaver Consulting Group | 130,000 | $437,000 | 0.21% |
Ikarian Capital, LLC | 304,161 | $1,022,000 | 0.13% |
ABNER HERRMAN & BROCK LLC | 265,000 | $890,000 | 0.12% |
S.C. Financial Services, Inc. | 15,285 | $51,000 | 0.06% |
JMAC ENTERPRISES LLC | 45,430 | $153,000 | 0.04% |
CFO4Life Group, LLC | 12,000 | $40,000 | 0.01% |
OSAIC HOLDINGS, INC. | 10,839 | $1,329,000 | 0.00% |
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 3,000 | $10,000 | 0.00% |
BOOTHBAY FUND MANAGEMENT, LLC | 29,186 | $98,000 | 0.00% |
RAYMOND JAMES & ASSOCIATES | 190,403 | $640,000 | 0.00% |